$98.18 Million in Sales Expected for Accuray Incorporated (ARAY) This Quarter

Brokerages expect Accuray Incorporated (NASDAQ:ARAY) to report sales of $98.18 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Accuray’s earnings. The highest sales estimate is $99.56 million and the lowest is $96.80 million. Accuray posted sales of $97.31 million during the same quarter last year, which suggests a positive year over year growth rate of 0.9%. The company is scheduled to report its next quarterly earnings results on Thursday, April 26th.

On average, analysts expect that Accuray will report full-year sales of $98.18 million for the current fiscal year, with estimates ranging from $399.40 million to $400.03 million. For the next fiscal year, analysts anticipate that the firm will post sales of $417.89 million per share, with estimates ranging from $417.47 million to $418.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Accuray.

How to Become a New Pot Stock Millionaire

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.05. Accuray had a negative return on equity of 44.66% and a negative net margin of 6.09%. The business had revenue of $100.33 million during the quarter, compared to analysts’ expectations of $90.31 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. The company’s quarterly revenue was up 14.7% compared to the same quarter last year.

ARAY has been the subject of several analyst reports. BidaskClub cut Accuray from a “buy” rating to a “hold” rating in a research note on Thursday, February 8th. Zacks Investment Research cut Accuray from a “buy” rating to a “hold” rating in a research note on Tuesday, March 27th. Finally, JPMorgan Chase cut Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 price target for the company. in a research note on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $7.21.

Shares of Accuray stock traded down $0.15 during trading hours on Monday, hitting $4.70. 337,496 shares of the company were exchanged, compared to its average volume of 583,732. Accuray has a 1 year low of $3.60 and a 1 year high of $6.15. The company has a debt-to-equity ratio of 2.66, a current ratio of 1.54 and a quick ratio of 0.99. The stock has a market capitalization of $413.67, a PE ratio of -13.06 and a beta of 1.73.

In other Accuray news, CEO Joshua Levine sold 8,675 shares of the stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $4.65, for a total value of $40,338.75. Following the completion of the transaction, the chief executive officer now owns 1,426,753 shares in the company, valued at $6,634,401.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 14,257 shares of company stock valued at $66,295 in the last quarter. 3.90% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in ARAY. The Manufacturers Life Insurance Company raised its position in Accuray by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 67,565 shares of the medical equipment provider’s stock worth $320,000 after acquiring an additional 3,246 shares in the last quarter. Bank of New York Mellon Corp raised its position in Accuray by 4.2% in the third quarter. Bank of New York Mellon Corp now owns 634,657 shares of the medical equipment provider’s stock worth $2,538,000 after acquiring an additional 25,354 shares in the last quarter. Russell Investments Group Ltd. raised its position in Accuray by 28.8% in the third quarter. Russell Investments Group Ltd. now owns 995,904 shares of the medical equipment provider’s stock worth $3,982,000 after acquiring an additional 222,424 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Accuray in the third quarter worth $191,000. Finally, Wells Fargo & Company MN raised its position in Accuray by 52.5% in the third quarter. Wells Fargo & Company MN now owns 94,664 shares of the medical equipment provider’s stock worth $379,000 after acquiring an additional 32,605 shares in the last quarter. Hedge funds and other institutional investors own 82.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/98-18-million-in-sales-expected-for-accuray-incorporated-aray-this-quarter.html.

Accuray Company Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Get a free copy of the Zacks research report on Accuray (ARAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply